RetinaDigest

Abstract not available — see full article for details.

Abstract not available — see full article for details.

This large retrospective US study found significant demographic disparities in likelihood of surgical repair following rhegmatogenous retinal detachment (RRD), with Black patients, female patients, and those with socioeconomic/psychosocial challenges being substantially less likely to undergo timely surgical intervention.

Abstract not available — see full article for details.

Amniotic membrane transplantation during vitrectomy achieved 100% macular hole closure in 8 eyes with extra-large or long-standing macular holes, with improvements in visual acuity, retinal sensitivity, and electrophysiological function and no amniotic membrane-related adverse events.

This systematic review and meta-analysis found that AI-driven diabetic retinopathy screening using ultra-widefield fundus images achieves acceptable sensitivity (85.0%) but limited specificity (72.5%), with an AUC of 0.870, though findings are constrained by a small number of available studies.

In this post hoc analysis of the KINGFISHER trial, monthly brolucizumab and aflibercept produced no statistically significant change in retinal nonperfusion indices over 52 weeks in DME patients, with no meaningful difference between the two agents.

Abstract not available — see full article for details.

Deep learning models for diabetic retinopathy detection perform well under matched training/testing conditions but degrade significantly across populations, with ConvNeXt-V2-Tiny demonstrating the most consistent screening performance when validated in a real-world Turkish clinical setting.

Curated synthetic retinal images generated via diffusion modeling (Medfusion) significantly improved diabetic retinopathy grading model performance, raising Quadratic Weighted Kappa from 0.64 to 0.77 and doubling sensitivity for proliferative DR detection in a limited-data setting.

A model-based cost-effectiveness analysis using 24-month LIGHTSITE III data found photobiomodulation (PBM) for intermediate dry AMD yields an ICER of $73,910 per QALY, falling below conventional US willingness-to-pay thresholds of $100,000–$150,000 per QALY.

This systematic review and meta-analysis of 19 studies found that chronic kidney disease (CKD), particularly reduced eGFR (<60 mL/min/1.73 m²) and dialysis exposure, is associated with modestly higher odds of AMD (OR = 1.27), with the strongest and most consistent association observed for non-exudative disease.

This comprehensive review synthesizes current advances in stem cell-based transplantation strategies for AMD, evaluating RPE and microglia cell platforms, graft configurations, genome editing approaches, and immune evasion techniques aimed at achieving durable outer retinal reconstruction and vision restoration.

Abstract not available — see full article for details.

Abstract not available — see full article for details.

In a randomized controlled trial of 'high-need' nAMD patients requiring frequent aflibercept 2 mg dosing, switching to faricimab successfully extended treatment intervals in 34.3% of eyes at 32 weeks compared to only 8.6% continuing aflibercept 2 mg (p=0.018), with over one-third achieving interval extension by 56 weeks.

Analysis of 34.5 million Medicare Part B anti-VEGF injections (2013–2023) reveals that community-level sociodemographic factors—particularly poverty, education, and racial composition—significantly influence whether providers use on-label versus off-label (bevacizumab) agents, generating an estimated $4.2 billion in differential spending.

Abstract not available — see full article for details.

PAMM was identified in nearly 24% of symptomatic post-cardiac surgery patients evaluated at a tertiary center, underscoring a significant burden of retinal microvascular ischemia in this population that is detectable by OCT even when visual acuity is preserved.

Researchers developed and validated two prognostic scoring systems—VAP (visual acuity + age) and VAP-O (adding OCT biomarkers)—that accurately predict 12-month visual outcomes in BRVO-associated macular edema, with the OCT-enhanced score demonstrating superior discriminative performance.

In this large longitudinal cohort study of 317 patients with sickle cell retinopathy, active smoking at the time of PSR diagnosis was the only factor significantly associated with progression to more advanced proliferative disease (HR 2.78), supporting aggressive smoking cessation counseling and closer surveillance in this subgroup.

This case report describes a rare pediatric case of systemic Degos disease (malignant atrophic papulosis) in which ocular findings—including choroidal nonperfusion, serous retinal detachment, and optic disc edema—preceded definitive diagnosis, highlighting the importance of recognizing ocular manifestations of this fatal vasculopathy.

Abstract not available — see full article for details.

Abstract not available — see full article for details.

This multicenter observational study confirms the long-term real-world safety of voretigene neparvovec-rzyl (VN) in 87 US patients over a median 3.7 years, with sustained visual improvements despite a 28% incidence of chorioretinal atrophy (CRA) that did not meaningfully impact functional outcomes.

A pooled analysis of three randomized controlled trials (n=295 participants, 327 eyes) demonstrated that revakinagene taroretcel-lwey significantly slowed MacTel type 2 disease progression over 24 months, reducing ellipsoid zone area loss by 36.2%, reading speed loss by 68.2%, and aggregate retinal sensitivity loss by 36.6% compared to sham.

This AAO systematic review of 26 studies found no significant difference in neurodevelopmental outcomes between anti-VEGF therapy and laser photocoagulation as primary treatment for ROP, though the evidence base lacks studies powered specifically for neurodevelopmental endpoints.

Abstract not available — see full article for details.

In a large multicenter cohort of 39,703 patients with undifferentiated uveitis, systemic autoimmune disease—particularly inflammatory spondyloarthropathy—emerged as the most common long-term etiology (25.93% at 15 years), with anatomical location strongly predicting the underlying diagnosis.

Non-infectious uveitis (NIU) is significantly associated with increased psychiatric comorbidities—including mood disorders, depression, anxiety, and substance abuse—with notably stronger associations in Black patients, yet mental health screening rates among NIU patients remain very low.

The Stalagmite Sign—multifocal, elongated hyperreflective preretinal deposits on SD-OCT with corresponding paravascular hyporeflective lesions on near-infrared reflectance imaging—is a high-specificity biomarker (99.1%, LR+ 24.5) for infectious peripheral retinitis, most commonly due to toxoplasmosis.

In this multicenter retrospective study of 46 eyes with APMPPE, pigment epithelium detachments (PEDs) were present in 56.5% of eyes and significantly associated with worse baseline visual acuity, bacillary layer detachment, and serous retinal detachment, suggesting PEDs may serve as an OCT biomarker of disease severity.

Abstract not available — see full article for details.

This systematic review and meta-analysis of experimental autoimmune uveitis (EAU) models found that monoclonal antibodies (mAbs) produced significantly greater reductions in both clinical and histologic inflammation compared to Type I interferons, supporting the superiority of targeted cytokine or co-stimulatory pathway inhibition in preclinical uveitis models.

Primary eye-preserving therapy for early cT3c retinoblastoma (neovascular glaucoma without buphthalmos) achieved a 49.4% globe salvage rate with partial visual recovery in nearly half of saved eyes, without compromising overall survival compared to primary enucleation.

High-dose intravitreal topotecan (100 μg/0.20 cc) for retinoblastoma can induce transient SD-OCT changes including microcystic macular edema, foveolar cystic edema, and ellipsoid zone disruption, all of which resolved completely within 10–16 weeks without permanent visual loss.

Abstract not available — see full article for details.

Abstract not available — see full article for details.

In a large IRIS Registry analysis, endophthalmitis rates after intravitreal injections varied significantly by agent, with corticosteroid implants (dexamethasone 12/10,000; fluocinolone acetonide 8–10/10,000) and pegcetacoplan (6.6/10,000) carrying substantially higher risk than anti-VEGF injections (3.3/10,000).